KR101509796B1 - Composition for preventing or treating obesity comprising blueberry fermentation extract - Google Patents
Composition for preventing or treating obesity comprising blueberry fermentation extract Download PDFInfo
- Publication number
- KR101509796B1 KR101509796B1 KR20090108173A KR20090108173A KR101509796B1 KR 101509796 B1 KR101509796 B1 KR 101509796B1 KR 20090108173 A KR20090108173 A KR 20090108173A KR 20090108173 A KR20090108173 A KR 20090108173A KR 101509796 B1 KR101509796 B1 KR 101509796B1
- Authority
- KR
- South Korea
- Prior art keywords
- blueberry
- extract
- fermented
- fermentation
- composition
- Prior art date
Links
- 240000000851 Vaccinium corymbosum Species 0.000 title claims abstract description 84
- 235000003095 Vaccinium corymbosum Nutrition 0.000 title claims abstract description 83
- 235000017537 Vaccinium myrtillus Nutrition 0.000 title claims abstract description 82
- 235000021014 blueberries Nutrition 0.000 title claims abstract description 82
- 208000008589 Obesity Diseases 0.000 title claims abstract description 48
- 235000020824 obesity Nutrition 0.000 title claims abstract description 48
- 239000000284 extract Substances 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000000855 fermentation Methods 0.000 title claims description 36
- 230000004151 fermentation Effects 0.000 title claims description 36
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 11
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241000235070 Saccharomyces Species 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 235000009200 high fat diet Nutrition 0.000 abstract description 21
- 210000000577 adipose tissue Anatomy 0.000 abstract description 10
- 230000037396 body weight Effects 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 abstract description 8
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 201000010063 epididymitis Diseases 0.000 abstract description 7
- 230000002093 peripheral effect Effects 0.000 abstract description 6
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000036541 health Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000037213 diet Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- 206010033307 Overweight Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- -1 biaryl ureas Chemical class 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000014171 carbonated beverage Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000020830 overeating Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000208422 Rhododendron Species 0.000 description 2
- 240000008424 Vaccinium ashei Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101150106280 Mchr1 gene Proteins 0.000 description 1
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 244000111388 Rubus occidentalis Species 0.000 description 1
- 235000003942 Rubus occidentalis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001409201 Tabebuia chrysantha Species 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 235000013468 Vaccinium ashei Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 235000015810 grayleaf red raspberry Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 블루베리 발효 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 블루베리 발효 추출물은 고지방 식이로 사육된 마우스의 체중을 감소시키며, 부고환주변지방 조직 및 신장주변지방 조직의 무게를 유의하게 감소시킴으로써, 비만의 예방 또는 치료에 유용하게 사용될 수 있다.The present invention relates to a composition for preventing or treating obesity containing a fermented blueberry extract as an active ingredient. The blueberry fermented extract according to the present invention can be used for preventing or treating obesity by decreasing the body weight of mice raised in a high fat diet and by significantly reducing the weight of epididymal peripheral fatty tissue and peripheral fat tissue.
Description
본 발명은 블루베리 발효 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating obesity containing a fermented blueberry extract as an active ingredient.
최근 경제성장과 생활방식의 변화에 따라 식습관에도 많은 변화가 있다. 특히, 바쁜 현대인들은 패스트푸드 등의 고열량 식이와 적은 운동량으로 인하여 체중 과다 및 비만이 증가하고 있다.Recent changes in diet and eating habits have been accompanied by changes in economic growth and lifestyle. Especially, busy modern people are overweight and obese because of high calorie diet such as fast food and low exercise amount.
체중 과다는 체질량 지수(BMI, 체중을 키의 제곱으로 나눈 비만 척도)가 25 이상 30 미만을 의미하며, 비만은 체질량 지수가 30 이상일 때 해당된다.Overweight refers to body mass index (BMI, obesity index divided by the square of body weight) between 25 and 30, and obesity is associated with body mass index> 30.
미국 성인의 3분의 2는 체중 과다이거나 비만이며, 체중 과다는 혈압과 콜레스테롤 수치를 높여 심장 질환 등의 각종 성인병의 발병률을 증가시키고, 비만은 심장병과 당뇨병, 관절염 및 일부 암 위험성을 증가시키고 있다.Two-thirds of US adults are overweight or obese, and overweight increases blood pressure and cholesterol levels to increase the incidence of various geriatric diseases such as heart disease, and obesity increases the risk of heart disease, diabetes, arthritis and some cancers .
체중 과다 및 비만은 성인뿐만 아니라 어린이나 청소년들에서도 동맥경화, 고혈압, 고지혈증 또는 심장질환 등의 각종 성인병의 발병률을 증가시키는 한 요인 이 되고 있다.Overweight and obesity are factors that increase the incidence of various adult diseases such as arteriosclerosis, hypertension, hyperlipidemia or heart disease not only in adults but also in children and adolescents.
이와 같이 비만은 모든 연령층에 걸쳐 영향을 주고 있으나, 특히 장년층의 발생빈도가 높다. 동양에서는 채식 위주의 생활습관으로 인해 비만증이 그리 많지 않았던 것으로 알려져 있으나, 현대에 들어서 서양문물의 영향으로 식생활 습관이 바뀌고 주거환경이 바뀌면서 동양인에게서도 점차 비만증이 증가하기 시작하였다.Thus, obesity affects all age groups, but especially among the elderly. In the Orient, it is known that obesity was not caused by vegetarianism lifestyle. However, in the modern times, dietary habits changed due to western culture and obesity gradually began to increase in Oriental people as housing environment changed.
또한 현대인은 과로, 과음, 스트레스 등으로 인하여 체력이 저하되며, 약 30~40%가 비만증을 가지고 있고, 그 중 약 10% 정도는 심각하거나 병적인 비만증을 나타낸다고 보고된 바 있다.In addition, modern people have been reported to suffer from overwork, overeating, stress, etc., about 30-40% of them have obesity, and about 10% of them have serious or pathological obesity.
비만은 체내에 지방이 과도하게 축적되어 있는 상태로 체중에서 지방이 차지하는 비율이 높은 상태를 나타내며, 단순성 비만과 2차성 비만(증후성 비만)으로 분류된다.Obesity is a state of excessive accumulation of fat in the body, indicating a high proportion of fat in body weight, and is classified as simple obesity and secondary obesity (symptom obesity).
단순성 비만의 원인으로는 과식, 운동부족, 및 기초대사의 저하 등을 들 수 있다. 임상적으로 비만으로 판정되는 경우의 대부분은 단순성 비만이다. 단순성 비만이 발현하여 그 상태가 지속되면, 각종 건강 장해를 일으키는 원인이 된다.Simplicity Causes of obesity include overeating, lack of exercise, and decreased basal metabolism. Most cases of clinical obesity are simple obesity. Simplicity If obesity develops and persists, it causes various health disorders.
2차성 비만은 임의의 기초질환이 원인이 되어 발생하는 비만으로, 내분비성 비만, 시상하부성 비만, 유전성 비만 또는 약제에 기인한 비만 등을 들 수 있다.Secondary obesity is obesity that occurs due to any underlying disease, including endocrine obesity, hypothalamic obesity, hereditary obesity, or obesity caused by medications.
비만의 주요 원인은 지방세포의 과성장에 있으며, 이는 뇌에서 명령하여 분비되는 렙틴(leptin)이라는 호르몬의 결핍으로 일어난다. 이러한 렙틴 호르몬의 결핍은 유전적으로 결핍이 일어난 경우를 제외하고는 과식, 노화로 인한 생체 내 물질대사의 약화, 체내에 과량 축적된 동물성 콜레스테롤에 의해 분비가 줄어든다.The main cause of obesity is overgrowth of adipocytes, which is caused by a deficiency of the hormone called leptin, which is secreted by the brain. These deficiencies of leptin hormone are secreted by over-accumulation of animal cholesterol in the body, weakening metabolism in vivo due to overeating, aging, except when genetically deficient.
비만은 그 자체가 고지혈증, 고혈압, 심혈관 질환, 가성 뇌종양(pseudotumor cerebri), 수면 무호흡증(sleep apnea), 암, 폐 고혈압(pulmonary hypertension), 담낭염(cholecystitis) 및 골관절염(osteoarthritis) 등의 각종 질환의 원인이 되거나, 또는 활동성의 저하 등의 문제를 야기한다. 또한, 비만은 여러 가지 질환이 원인이 되어 합병증으로 나타나는 경우도 있다.Obesity itself is a cause of various diseases such as hyperlipemia, hypertension, cardiovascular disease, pseudotumor cerebri, sleep apnea, cancer, pulmonary hypertension, cholecystitis and osteoarthritis Or a decrease in activity. In addition, obesity may be caused by various diseases and may be a complication.
비만에 대한 연구로는, 2002년 인디아에서 가르시니아 캄보지아(garcinia cambogia)로부터 HCA(hydroxycitric acid)의 분리·정제 관련 연구 결과가 발표되었으며(Bhabani et al, 2002), 2005년 미국에서는 MCH-R1(melanin concentrating hormone receptor1)을 포함하는 바이아릴 우레아(biaryl ureas)의 비만증 치료에 관한 섭취량 변화에 따른 BW(bodyweight) 연구결과를 발표하였다(Palani et al, 2005). 2005년 일본에서는 콩단백질의 섭취에 따른 랫트의 체중증가 억제와 섭취량 감소, 중성지방 감소, 콜레스테롤 감소 등의 연구결과를 발표(Tachibana et al, 2005)하는 등 세계 각국에서 항비만 치료 및 예방에 관한 연구들이 꾸준히 진행되고 있다.Studies on obesity have been published (Bhabani et al, 2002) in 2002 in India on the separation and purification of HCA from garcinia cambogia (Bhabani et al, 2002) and in the United States in 2005 MCH-R1 (melanin (Palani et al., 2005). In this study, we investigated the effects of dietary supplementation on body weight (BW) in diabetic patients treated with biaryl ureas. In 2005, Japan announced the results of studies on the inhibition of weight gain in rats due to the consumption of soy protein, the decrease of intake, the decrease of triglyceride and the decrease of cholesterol (Tachibana et al, 2005) Studies are progressing steadily.
현재 사용되고 있는 비만증을 치료하기 위한 약물요법으로는 식욕억제제, 지방흡수억제제 또는 지방연소제 등이 있다. 식욕억제제로는 덱스플렌플루라민 (dexflenfluramine), 페닐알라닌, 타이로신 및 메티오닌 등이 있으며, 지방흡수억제제로는 올리스타트(orlistat), 키토산 등이 있고, 지방연소제로는 시부트라민, 에페드린, 카페인, 지실, 가르시니아 캄보지아, L-카르니친, 글루코만난, 갈락토만난, 피콜린산 크롬(chromium picolinate) 등이 있다. 그러나, 이들 비만 치료제들 은 일시적인 체중감소 효과를 나타낼 수 있으나, 약물 의존성 등의 부작용을 일으킬 위험성이 있다. 또한, 투여한 환자에게 단기간에 내성이 생겨버리는 경우도 있기 때문에, 장기간 연속하여 사용할 수 없다는 문제점도 있다.Drug therapy for treating obesity currently in use includes an appetite suppressant, a fat absorption inhibitor, or a fat burner. Examples of the appetite suppressant include dexflenfluramine, phenylalanine, tyrosine, and methionine. Examples of the fat absorption inhibitor include orlistat and chitosan. Examples of the fat burning agent include sibutramine, ephedrine, caffeine, Cambogia, L-carnitine, glucomannan, galactomannan, chromium picolinate, and the like. However, these obesity treatments may exhibit a temporary weight loss effect, but they may cause side effects such as drug dependency. In addition, there is also a problem that the patient to be administered can not be used continuously for a long period of time because the patient may develop resistance for a short period of time.
따라서, 많은 연구자들은 장기간 사용하여도 인체에 대해 안전하고 부작용이 적은 비만 억제제를 개발하기 위하여 생약재를 이용한 연구를 수행하고 있다.Therefore, many researchers are conducting research using herbal medicines to develop an obesity inhibitor that is safe for the human body and has little side effects even after long-term use.
한편, 블루베리는 진달래과 산앵도나무속의 관목성 식물로서, 전 세계적으로 400여종이 있으며, 아프리카, 칠레, 호주, 일본, 미국, 캐나다, 핀란드, 스웨덴 등 추운 지역까지 분포되어 있다. 현재, 주로 사용되고 있는 종은 북아메리카 원산으로 20 여종이 알려져 있으며, 하이부시 블루베리(highbush blueberry, V. Corymbosum), 래비트아이 블루베리(rabbiteye blueberry, V. Ashei) 및 로부시 블루베리(lowbusy blueberry, V. Angustrafolium) 등 3품종이 주종을 이루고 있다. 우리나라에는 정금나무, 산앵도나무 등이 있다. 블루베리 과실은 보랏빛이 나는 작은 구슬만한 크기의 소과종으로, 당도는 품종에 따라 11~14°Brx 이며, 특유의 신미와 방향이 있고, 당과 유기산이 풍부하며, 특히 기능성 물질인 안토시아닌이 다량 함유되어 있다. 블루베리는 시력개선 효과, 망막의 변성과 백내장 방지 효과, 혈중콜레스테롤 및 혈당 감소 효과, 골밀도 감소를 저해하는 효과를 가진다고 알려져 있다. 또한, 블루베리는 항암효과(Seeram NP, Adams LS, Zhang Y, Lee R, Sand D, Scheuller HS, Heber D. 2006, Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J Agric Food Chem., Dec 13;54(25):9329-39.)가 있다고 알려져 있다. 반면, 블루베리 생과일 고지방식이에서 비만 유발 효과(Prior RL, Wu X, Gu L, Hager TJ, Hager A, Howard LR., 2008, Whole berries versus berry anthocyanins: interactions with dietary fat levels in the C57BL/6J mouse model of obesity. J Agric Food Chem., Feb 13;56(3):647-653. Epub 2008 Jan 23)가 있다는 연구결과가 발표되었다. 고지방식이에서 블루베리 섭취에 의한 비만 유발 효과의 실험결과는 표 1에 나타내었다.On the other hand, blueberries are shrubs of rhododendrons and rhododendrons. There are about 400 species worldwide, and they are distributed to cold regions such as Africa, Chile, Australia, Japan, USA, Canada, Finland and Sweden. At present, 20 species are known from North America and the most commonly used species are highbush blueberry, V. corymbosum, rabbiteye blueberry, V. Ashei and lowbusy blueberry , V. Angustrafolium). In Korea, there are pure gold trees and wild angel trees. Blueberry fruit is a small bead of the size of a purple bead. The sugar content varies from 11 to 14 ° Brx depending on the varieties. It has a distinctive flavor and aroma, rich in sugars and organic acids, and especially anthocyanins, . Blueberries are known to have the effect of improving vision, retinal degeneration and cataract prevention effect, blood cholesterol and blood glucose lowering effect, and reduction of bone density. In addition, the blueberry has an anticancer effect (Seeram NP, Adams LS, Zhang Y, Lee R, Sand D, Scheuller HS, Heber D. 2006, Blackberry, black raspberry, blueberry, cranberry, red raspberry, apoptosis of human cancer cells in vitro. J Agric Food Chem., Dec 13: 54 (25): 9329-39). On the other hand, the obesity-inducing effect of blueberry on the high fat diet (Prior RL, Wu X, Gu L, Hager TJ, Hager A, Howard L R. 2008, Whole berries versus berry anthocyanins: interactions with dietary fat levels in the C57BL / 6J J Agric Food Chem., Feb 13; 56 (3): 647-653. Epub 2008 Jan 23). Table 1 shows the results of obesity induction by blueberry ingestion in high fat diet.
따라서, 고지방식이를 하는 현대인에게 블루베리 생과일의 섭취는 비만을 심화시킬 우려가 있다. Therefore, the consumption of blueberry fresh fruits to modern people who do the high-fat diet, there is a concern that deepening obesity.
본 발명자들은 인체에 무해하며 비만의 예방 또는 치료 효과를 갖는 약제를 개발하기 위하여 생약재 중에서 탐색하던 중, 블루베리 발효 추출물이 고지방 식이로 사육된 마우스의 체중을 감소시키며, 부고환주변지방 조직 및 신장주변지방 조직의 무게를 유의하게 감소시킴을 확인하고, 본 발명을 완성하였다.The inventors of the present invention have found that blueberry fermented extract reduces the body weight of mice raised in a high fat diet while developing a drug that is harmless to human body and has the effect of preventing or treating obesity, And the weight of the adipose tissue was significantly reduced, thereby completing the present invention.
본 발명은 블루베리 발효 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 조성물을 제공하고자 한다.The present invention is intended to provide a composition for preventing or treating obesity containing a fermented blueberry extract as an active ingredient.
본 발명은 블루베리 발효 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 조성물을 제공한다.The present invention provides a composition for preventing or treating obesity containing a fermented blueberry extract as an active ingredient.
상기 조성물은 약학 조성물 및 식품 조성물을 포함한다.The composition comprises a pharmaceutical composition and a food composition.
이하, 본 발명에 대해 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 조성물의 유효성분인 블루베리 발효 추출물은, 블루베리를 통상적인 방법으로 발효시켜 블루베리 발효 건조물을 얻은 후, 블루베리 발효 건조물을 통상적인 방법으로 추출시켜 얻을 수 있다. 통상적인 추출 방법은 초음파 추출법, 여과법 및 환류 추출법 등을 포함할 수 있으나, 이에 한정되지 않는다.The blueberry fermented extract as an active ingredient of the composition of the present invention can be obtained by fermenting blueberry with a conventional method to obtain a fermented blueberry dried product and then extracting the fermented blueberry dried product by a conventional method. Typical extraction methods include, but are not limited to, ultrasonic extraction, filtration, and reflux extraction.
본 발명에서는 블루베리 발효 추출물을 하기와 같은 방법으로 발효, 추출 및 분리하여 얻을 수 있다. 먼저, 블루베리를 세척하고 건조한 후 분쇄한다. 분쇄된 블루베리를 통상의 방법으로 발효한다. 발효시 사용된 효모는 사카로마이세스 세레비시아(Saccharomyces cerevisiae)가 바람직하나, 이에 한정되지 않는다. 발효온도는 10~30℃, 발효기간은 3~15일, 바람직하게는 1주일이다. 발효를 촉진하기 위하여, 설탕, 포도당 등을 5-30% 정도 첨가할 수도 있다. 발효가 완료된 후 발효액을 열풍건조나 동결건조로 건조시켜 블루베리 발효 건조물을 얻는다. 상기에서 얻은 블루베리 발효 건조물을 물, C1~C4의 알콜 또는 물과 C1~C4의 알콜의 혼합용매에 침지하여 100~350rpm의 속도로 교반하면서 추출한다. 이때, 용매의 부피는 분쇄한 시료 중량의 5~15배, 추출시간은 1~5일, 바람직하게는 3일이다. 상기 C1~C4의 알콜은 메탄올 또는 에탄올 중에서 선택될 수 있으며, 바람직하게는 에탄올이다. 이후, 추출액을 여과하고 얻어진 상등액의 용매를 감압 하에 농축시켜 블루베리 발효 추출물을 얻는다.In the present invention, the blueberry fermentation extract can be obtained by fermentation, extraction and separation as follows. First, the blueberries are washed, dried and then ground. The pulverized blueberries are fermented by a conventional method. The yeast used in the fermentation is preferably Saccharomyces cerevisiae, but is not limited thereto. The fermentation temperature is 10 to 30 占 폚, the fermentation period is 3 to 15 days, preferably 1 week. In order to promote fermentation, about 5 to 30% of sugar, glucose and the like may be added. After the fermentation is completed, the fermentation liquid is dried by hot air drying or freeze drying to obtain a fermented blueberry dried material. The above-obtained fermented blueberry fermentation product is dipped in a mixed solvent of water, a C 1 to C 4 alcohol or water and a C 1 to C 4 alcohol, and extracted with stirring at a speed of 100 to 350 rpm. At this time, the volume of the solvent is 5 to 15 times the weight of the pulverized sample, and the extraction time is 1 to 5 days, preferably 3 days. The C 1 -C 4 alcohol may be selected from methanol or ethanol, preferably ethanol. Thereafter, the extract is filtered, and the solvent of the resulting supernatant is concentrated under reduced pressure to obtain a blueberry fermented extract.
본 발명에 따른 블루베리 발효 추출물은 고지방 식이로 사육된 마우스의 체중을 감소시키며, 부고환주변지방 조직 및 신장주변지방 조직의 무게를 유의하게 감소시킨다. 따라서, 본 발명에 따른 블루베리 발효 추출물은 비만의 예방 또는 치료에 유용한 의약품 및 건강식품으로 사용될 수 있다.The blueberry fermented extract according to the present invention reduces the body weight of the mice raised in the high fat diet and significantly reduces the weight of the epididymal and adipose tissue. Therefore, the blueberry fermented extract according to the present invention can be used as medicines and health foods useful for prevention or treatment of obesity.
본 발명의 조성물은 블루베리 발효 추출물과 함께 비만의 예방 또는 치료 효과를 갖는 공지의 유효성분을 1종 이상 함유할 수 있다.The composition of the present invention may contain at least one known active ingredient having the effect of preventing or treating obesity together with the blueberry fermented extract.
본 발명의 조성물은, 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약학적으로 허용가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로오스 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당분야의 적정한 방법으로 또는 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.The composition of the present invention may further comprise at least one pharmaceutically acceptable carrier in addition to the above-described effective ingredients for administration. The pharmaceutically acceptable carrier may be a mixture of saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components. If necessary, an antioxidant, , And other conventional additives such as a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using appropriate methods in the art or by the method disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA.
본 발명의 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다. 상기 블루베리 발효 추출물의 일일 투여량은 약 0.1~100㎎/㎏, 바람직하게는 약 30~80㎎/㎏, 더욱 바람직하게는 약 50~60㎎/㎏이며, 하루 일회 내지 수회에 나누어 투여하는 것이 바람직하다.The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may be appropriately determined depending on the patient's weight, age, , Diet, administration time, method of administration, excretion rate, and severity of the disease. The daily dose of the blueberry fermented extract is about 0.1 to 100 mg / kg, preferably about 30 to 80 mg / kg, more preferably about 50 to 60 mg / kg, and is administered once a day to several times a day .
본 발명의 조성물은 비만의 예방 또는 치료를 위하여 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention can be used alone or in combination with methods for the prevention or treatment of obesity or using surgery, hormone therapy, drug therapy and biological response modifiers.
본 발명의 조성물은 비만 억제를 목적으로 건강식품에 첨가될 수 있다. 본 발명의 블루베리 발효 추출물을 식품 첨가물로 사용할 경우, 상기 블루베리 발효 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에는 본 발명의 블루베리 발효 추출물은 원료에 대하여 15 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The composition of the present invention may be added to a health food for the purpose of obesity suppression. When the blueberry fermented extract of the present invention is used as a food additive, the blueberry fermented extract may be added as it is or may be used together with other food or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of foods or beverages, the blueberry fermented extract of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토오스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 시클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 약 0.01~0.04g, 바람직하게는 약 0.02~0.03g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01~0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples.
실시예 1Example 1 : 블루베리 발효 수 추출물의 제조 : Preparation of Blueberry Fermented Water Extract
1. 블루베리 발효 건조물의 제조1. Preparation of fermented blueberry dried product
블루베리를 물로 깨끗이 세척하고 건조한 후 분쇄하였다. 분쇄된 블루베리를 통상의 방법으로 발효하였다. 발효시 사용된 효모는 사카로마이세스 세레비시아 (Saccharomyces cerevisiae)이었으며, 발효온도는 10~30℃, 발효기간은 1주일로 하였다. 발효를 촉진하기 위하여, 설탕, 포도당 등을 5-30% 정도 첨가할 수도 있다. 발효가 완료된 후 발효액을 열풍건조나 동결건조로 건조시켜 블루베리 발효 건조물을 얻었다.The blueberries were cleanly washed with water, dried and then ground. The pulverized blueberries were fermented by a conventional method. The yeast used in the fermentation was Saccharomyces cerevisiae, the fermentation temperature was 10 to 30 ° C, and the fermentation period was one week. In order to promote fermentation, about 5 to 30% of sugar, glucose and the like may be added. After completion of the fermentation, the fermentation broth was dried by hot air drying or freeze-drying to obtain a blueberry fermentation product.
2. 블루베리 발효 수 추출물의 제조2. Preparation of Blueberry Fermented Water Extract
상기 1에서 제조한 블루베리 발효 건조물 0.1㎏을 추출 용기에 넣고, 여기에 블루베리 발효 건조물 중량에 대해 10배의 물을 가하고 3일 동안 침지하여 추출하였다. 추출액을 여과하고, 얻어진 상등액의 용매를 감압 하에 농축시켜 블루베리 발효 수 추출물 54.3g(수율 54.3%(w/w))을 얻었다.0.1 kg of the fermented blueberry fermentation product prepared in 1 above was placed in an extraction container, and 10 times water was added to the weight of the fermented blueberry fermentation product, followed by immersion for 3 days. The extract was filtered, and the solvent of the resulting supernatant was concentrated under reduced pressure to obtain 54.3 g (yield: 54.3% (w / w)) of blueberry fermented water extract.
실시예 2Example 2 : 블루베리 발효 에탄올 추출물의 제조 : Preparation of Blueberry Fermented Ethanol Extract
상기 실시예 1의 1에서 제조한 블루베리 발효 건조물 0.1㎏을 추출 용기에 넣고, 여기에 블루베리 발효 건조물 중량에 대해 10배의 100% 에탄올(HPLC 등급)을 가하고 상온에서 3일 동안 침지하여 교반기(180rpm)를 사용하여 추출하였다(3회 반복). 추출액을 여과하고, 얻어진 상등액의 용매를 감압 하에 농축시켜 블루베리 발효 에탄올 추출물 23.5g(수율 23.5%(w/w))을 얻었다.0.1 kg of the dried fermented blueberry prepared in Example 1 was placed in an extraction container, and 10 times 100% ethanol (HPLC grade) was added to the weight of the fermented blueberry fermentation product. The fermented product was immersed in the fermentation broth for 3 days at room temperature, (180 rpm) (3 repetitions). The extract was filtered, and the solvent of the resulting supernatant was concentrated under reduced pressure to obtain 23.5 g (yield: 23.5% (w / w)) of blueberry fermented ethanol extract.
실시예 3Example 3 : 블루베리 발효 메탄올 추출물의 제조 : Preparation of Blueberry Fermented Methanol Extract
상기 실시예 1의 1에서 제조한 블루베리 발효 건조물 0.1㎏을 추출 용기에 넣고, 여기에 블루베리 발효 건조물 중량에 대해 10배의 100% 메탄올(HPLC 등급)을 가하고 상온에서 3일 동안 침지하여 교반기(180rpm)를 사용하여 추출하였다(3회 반복). 추출액을 여과하고, 얻어진 상등액의 용매를 감압 하에 농축시켜 블루베리 발효 에탄올 추출물 31.6g(수율 31.6%(w/w))을 얻었다.0.1 kg of the fermented blueberry fermentation product prepared in Example 1 was placed in an extraction container, 10 times 100% methanol (HPLC grade) was added to the weight of the fermented blueberry fermentation product, and the mixture was immersed at room temperature for 3 days. (180 rpm) (3 repetitions). The extract was filtered, and the solvent of the resulting supernatant was concentrated under reduced pressure to obtain 31.6 g (yield 31.6% (w / w)) of ethanol extract of fermented blueberry.
실험예 1Experimental Example 1 : 체중변화 및 지방조직의 무게 측정 : Weight change and weight measurement of adipose tissue
본 발명에 따른 블루베리 발효 추출물이 체중변화 및 지방조직의 무게에 미치는 영향을 확인하기 위하여, 하기와 같은 실험을 수행하였다.In order to confirm the effect of the fermented blueberry extract according to the present invention on weight change and weight of adipose tissue, the following experiment was conducted.
1. 체중변화 측정1. Weight change measurement
생후 4주 정도의 수컷 ICR 마우스(오리엔트 바이오, 한국)를 3개군[정상식이군(대조군), 고지방식이군, 블루베리 발효 추출물 포함 고지방식이군]으로 나누고, 1군에 5마리씩 할당하였다. 상기 실험동물에 AIN-93 diet 정상식이, 고지방식이(칼로리 45% 증가) 및 음용수를 자유 섭취시키고 30일 정도 충분하게 적응시켜 사육하였다. 블루베리 발효 추출물 포함 고지방식이군에서는 상기 실시예 2에서 제조한 블루베리 발효 에탄올 추출물을 1% 정도로 고지방식이에 혼합하여 30일 동안 식이량 4g/1마리, 1일 1회 섭취시켰다. AIN-93 diet 정상식이 조성(%) 및 고지방식이 조성(%)은 표 2에 나타내었다. 고지방 식이로 사육된 마우스의 체중변화는 실험개시일로부터 1주일마다 측정하였다. 체중변화는 도 1에 나타내었다.Male ICR mice (Orient Bio, Korea) were divided into three groups (normal diet (control group), high fat diet, high fat diet including blueberry fermented extract) for 4 weeks after birth and 5 rats were assigned to each group. The experimental animals were fed with the AIN-93 diet diet, the high-fat diet (45% increase in calorie), and the free consumption of drinking water for 30 days. In the high-fat diet containing blueberry fermented extract, the blueberry fermented ethanol extract prepared in Example 2 was mixed in a high fat diet at a ratio of about 1%, and the diet was fed at a feed rate of 4 g / day for one day, once a day for 30 days. Table 2 shows the composition of the AIN-93 diet (%) and the composition of the high-fat diet (%). Changes in body weight of mice fed the high fat diet were measured every week from the start of the experiment. Body weight changes are shown in Fig.
도 1에 나타난 바와 같이, 본 발명에 따른 블루베리 발효 추출물을 포함하는 고지방식이군은 고지방식이군에 비해 현저한 체중감소 효과를 나타내었다.As shown in FIG. 1, the high-fat diet group containing the fermented blueberry extract according to the present invention showed a remarkable weight loss effect as compared with the high fat diet group.
2. 지방조직의 무게 측정2. Weighing of fatty tissue
고지방 식이로 사육된 마우스의 지방조직의 무게는 부고환주변지방 (epididymal fat) 조직과 신장주변지방(perirenal fat) 조직을 절개한 후 측정하였다. 부고환주변지방 조직과 신장주변지방 조직의 무게는 각각 도 2 및 도 3에 나타내었다.The weight of adipose tissue in the mice fed the high fat diet was measured after incising epididymal fat tissue and perirenal fat tissue. The weight of the epididymal adipose tissue and the adipose tissue around the kidney are shown in FIG. 2 and FIG. 3, respectively.
도 2 및 도 3에 나타난 바와 같이, 본 발명에 따른 블루베리 발효 추출물을 포함하는 고지방식이군은 고지방식이군에 비해 부고환주변지방 조직 및 신장주변지방 조직의 무게가 유의적으로 감소하였다.As shown in FIG. 2 and FIG. 3, the weight of the epididymal perihepatic fat tissue and the peripheral fat tissue of the high fat diet group containing the fermented extract of blueberry according to the present invention was significantly lower than that of the high fat diet group.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
제제예 1Formulation Example 1 : 약학적 제제의 제조 : Preparation of pharmaceutical preparations
1. 산제의 제조1. Manufacturing of powder
블루베리 발효 추출물 2gBlueberry fermented extract 2g
유당 1gLactose 1g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above components were mixed and packed in airtight bags to prepare powders.
2. 정제의 제조2. Preparation of tablets
블루베리 발효 추출물 100㎎Blueberry fermented extract 100mg
옥수수전분 100㎎100 mg of corn starch
유 당 100㎎100 mg of milk
스테아린산 마그네슘 2㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
3. 캡슐제의 제조3. Preparation of capsules
블루베리 발효 추출물 100㎎Blueberry fermented extract 100mg
옥수수전분 100㎎100 mg of corn starch
유 당 100㎎100 mg of milk
스테아린산 마그네슘 2㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
제제예 2Formulation Example 2 : 식품의 제조 : Manufacturing of food
본 발명의 블루베리 발효 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the blueberry fermented extract of the present invention were prepared as follows.
1. 조리용 양념의 제조1. Preparation of cooking seasoning
블루베리 발효 추출물 20~95 중량%로 건강 증진용 조리용 양념을 제조하였다.And 20 to 95% by weight of a blueberry fermented extract to prepare a cooking sauce for health promotion.
2. 토마토 케찹 및 소스의 제조2. Manufacture of tomato ketchup and sauce
블루베리 발효 추출물 0.2~1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.0.2 to 1.0% by weight of blueberry fermented extract was added to tomato ketchup or sauce to prepare healthy tomato ketchup or sauce.
3. 밀가루 식품의 제조3. Manufacture of flour food
블루베리 발효 추출물 0.5~5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.5 to 5.0% by weight of blueberry fermented extract was added to wheat flour, and bread, cake, cookies, crackers and noodles were prepared by using this mixture to prepare health improving foods.
4. 스프 및 육즙(gravies)의 제조4. Manufacture of soups and gravies
블루베리 발효 추출물 0.1~5.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1 to 5.0% by weight of blueberry fermented extract was added to soup and juice to prepare health promotion meat product, noodle soup and juice.
5. 그라운드 비프(ground beef)의 제조5. Manufacture of ground beef
블루베리 발효 추출물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.10% by weight of blueberry fermented extract was added to ground beef to prepare ground beef for health promotion.
6. 유제품(dairy products)의 제조6. Manufacture of dairy products
블루베리 발효 추출물 5~10 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5 to 10% by weight of fermented blueberry extract was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
제제예 3Formulation Example 3 : 음료의 제조 : Manufacture of beverages
1. 탄산음료의 제조1. Manufacture of carbonated beverages
설탕 5~10%, 구연산 0.05~0.3%, 카라멜 0.005~0.02%, 비타민 C 0.1~1%의 첨가물을 혼합하고, 여기에 79~94%의 정제수를 섞어서 시럽을 만들고, 상기 시럽을 85~98℃에서 20~180초간 살균하여 냉각수와 1:4의 비율로 혼합한 다음 탄산가스를 0.5~0.82%를 주입하여 본 발명의 블루베리 발효 추출물을 함유하는 탄산음료를 제조하였다.The syrup is prepared by mixing 5 to 10% of sugar, 0.05 to 0.3% of citric acid, 0.005 to 0.02% of caramel and 0.1 to 1% of vitamin C and 79 to 94% of purified water to prepare syrup, ° C for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 4, and 0.5 to 0.82% of carbon dioxide gas was injected to prepare carbonated beverages containing the blueberry fermented extract of the present invention.
2. 건강음료의 제조2. Manufacture of health drinks
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 블루베리 발효 추출물을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.The ingredients such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%) and the blueberry fermentation extract were blended homogeneously, Bottles, plastic bottles, etc.
3. 야채쥬스의 제조3. Manufacture of vegetable juice
블루베리 발효 추출물 5g을 토마토 또는 당근 쥬스 1,000㎖에 가하여 건강 증진용 야채쥬스를 제조하였다.Healthy vegetable juice was prepared by adding 5 g of blueberry fermented extract to 1,000 ml of tomato or carrot juice.
4. 과일쥬스의 제조4. Manufacture of fruit juice
블루베리 발효 추출물 1g을 사과 또는 포도 쥬스 1,000㎖에 가하여 건강 증진용 과일쥬스를 제조하였다.1 g of the fermented blueberry extract was added to 1,000 ml of apple or grape juice to prepare health promotion fruit juice.
본 발명에 따른 블루베리 발효 추출물은 고지방 식이로 사육된 마우스의 체중을 감소시키며, 부고환주변지방 조직 및 신장주변지방 조직의 무게를 유의하게 감소시킴으로써, 비만의 예방 또는 치료에 유용하게 사용될 수 있다.The blueberry fermented extract according to the present invention can be used for preventing or treating obesity by decreasing the body weight of mice raised in a high fat diet and by significantly reducing the weight of epididymal peripheral fatty tissue and peripheral fat tissue.
도 1은 본 발명에 따른 블루베리 발효 추출물의 체중 감소 효과를 나타낸 도이다.Brief Description of the Drawings Fig. 1 is a graph showing a weight loss effect of a fermented blueberry extract according to the present invention. Fig.
도 2는 본 발명에 따른 블루베리 발효 추출물의 부고환주변지방 조직의 무게 감소 효과를 나타낸 도이다.FIG. 2 is a graph showing a weight-reducing effect of the epididymal peripheral fat tissue of the blueberry fermentation extract according to the present invention.
도 3은 본 발명에 따른 블루베리 발효 추출물의 신장주변지방 조직의 무게 감소 효과를 나타낸 도이다.FIG. 3 is a graph showing a weight-reducing effect of fat surrounding fat tissue of a fermented blueberry extract according to the present invention.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090108173A KR101509796B1 (en) | 2009-11-10 | 2009-11-10 | Composition for preventing or treating obesity comprising blueberry fermentation extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090108173A KR101509796B1 (en) | 2009-11-10 | 2009-11-10 | Composition for preventing or treating obesity comprising blueberry fermentation extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110051543A KR20110051543A (en) | 2011-05-18 |
KR101509796B1 true KR101509796B1 (en) | 2015-04-10 |
Family
ID=44361792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20090108173A KR101509796B1 (en) | 2009-11-10 | 2009-11-10 | Composition for preventing or treating obesity comprising blueberry fermentation extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101509796B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101830102B1 (en) | 2015-11-26 | 2018-02-21 | 전라북도(농업기술원) | Manufacturing method for fermented beverage using blueberry |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160046258A (en) | 2014-10-20 | 2016-04-28 | 목포대학교산학협력단 | Composition for treating or preventing obesity containing extract of seed of vaccinium spp. |
KR102323299B1 (en) * | 2014-12-10 | 2021-11-08 | 경북대학교 산학협력단 | Aronia melanocarpa fermented ethanol extracts having anti-oxidative and antimicrobial activity and use thereof |
KR102025887B1 (en) | 2017-09-13 | 2019-09-26 | 농업회사법인 베리베리코리아 주식회사 | Blueberry tart and the preparing process thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002153240A (en) | 2000-11-24 | 2002-05-28 | Kinji Ishida | Composition for preventing and ameliorating obesity and food and drink using the same |
KR20050115874A (en) * | 2003-03-03 | 2005-12-08 | 산에이겐 에후.에후. 아이. 가부시키가이샤 | Adiponectin expression promoter |
-
2009
- 2009-11-10 KR KR20090108173A patent/KR101509796B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002153240A (en) | 2000-11-24 | 2002-05-28 | Kinji Ishida | Composition for preventing and ameliorating obesity and food and drink using the same |
KR20050115874A (en) * | 2003-03-03 | 2005-12-08 | 산에이겐 에후.에후. 아이. 가부시키가이샤 | Adiponectin expression promoter |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101830102B1 (en) | 2015-11-26 | 2018-02-21 | 전라북도(농업기술원) | Manufacturing method for fermented beverage using blueberry |
Also Published As
Publication number | Publication date |
---|---|
KR20110051543A (en) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101184666B1 (en) | Composition for improving physiological activity of positive constitution | |
KR100966719B1 (en) | Composition comprising Orostachys japonicus extract for inhibiting obesity and for preventing or treating hyperlipidemia | |
KR101320738B1 (en) | The method of extracting carotinoid pigments of micro algae and composition comprising the extracted fucoxanthin for preventing or treating obesity or diabetes | |
KR101509796B1 (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
KR101261029B1 (en) | Composition for preventing or improving the diabete containing suaeda japonica | |
JPWO2004112817A1 (en) | Celery family-derived extract and method for producing the same | |
KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
KR102112599B1 (en) | Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component | |
KR101447121B1 (en) | Composition or health food for xanthine oxidase inhibition containing extract of unripe quince | |
KR102239066B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
KR20110051545A (en) | Composition for preventing or treating gout comprising mulberry fermentation extract | |
KR101069844B1 (en) | A composition for the prevention and treatment of edema or dermatitis containing Angelica decursiva extract or fraction thereof as an active ingredient | |
KR20160026595A (en) | Composition for preventing or improving obesity and obesity-related disease comprising mixture of Coix lacryma-jobi L. var., Lentinus edodes, Poncirus trifoliata Rafin and Corn silk | |
KR101811210B1 (en) | Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component | |
JP2019073476A (en) | Agent for atp production promotion | |
KR101344564B1 (en) | Composition comprising extract of hot peppers and Chinese peppers for preventing or treating of obesity or hyperlipidemia | |
KR101109771B1 (en) | Composition for prevention or treatment of heart diseases comprising extract of yuzu | |
KR20120040890A (en) | Blueberry fermentation extract as an effective components for prevention and treatment of obesity | |
KR101325825B1 (en) | Composition comprising oenanthe javanica organic acid extract for anti-inflammation | |
KR20110051541A (en) | Composition for preventing or treating gout comprising black galic extract | |
US20070092587A1 (en) | Extract from plant of japanese parsley family and process for producing the same | |
KR101438278B1 (en) | Composition for Prevention or Treatment of Circulatory Disorder Comprising AFG | |
KR102485676B1 (en) | A composition for improving, preventing and treating of obesity comprising Ulva pertusa Kjellman extracts | |
KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
KR101293032B1 (en) | Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
FPAY | Annual fee payment |
Payment date: 20180312 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190311 Year of fee payment: 5 |
|
R401 | Registration of restoration |